SWEAT GLAND TUMOUR

This adverse event was reported 235 times

SWEAT GLAND TUMOUR is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ARSENIC TRIOXIDE 4 0.0017
1 ESTRADIOL VALERATE 1 0.0013
2 PURIXAN 1 0.0013
3 REPAGLINIDE 7 0.0009
4 TECLISTAMAB-CQYV 2 0.0008
5 BUSULFAN 13 0.0008
6 NARATRIPTAN 1 0.0007
7 RANOLAZINE 7 0.0007
8 MITOXANTRONE HYDROCHLORIDE 4 0.0006
9 ETOPOSIDE 44 0.0006
See all drugs enriched for association with SWEAT GLAND TUMOUR

SWEAT GLAND TUMOUR is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Glinide [EPC] 7 0.0008
1 Anti-anginal [EPC] 7 0.0007
2 Topoisomerase Inhibitor [EPC] 44 0.0006
3 Aryl Hydrocarbon Receptor Agonist [EPC] 1 0.0005
4 Tyrosine Kinase 2 Inhibitor [EPC] 1 0.0003
5 Alkylating Drug [EPC] 76 0.0003
6 Lipid-based Polyene Antifungal [EPC] 4 0.0003
7 Alkaloid [EPC] 5 0.0002
8 Barbiturate [EPC] 2 0.0002
9 Nucleoside Metabolic Inhibitor [EPC] 33 0.0001
See all drug classes enriched for association with SWEAT GLAND TUMOUR